Latest news with #NodThera
Yahoo
4 days ago
- Business
- Yahoo
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796Philadelphia, PA, June 4, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces that the first patients have been dosed in its Phase 2 RESOLVE-1 (RESolution Of infLammation to treat obesity and cardioVascular disEase) clinical trial investigating the potential of its lead candidate, oral NLRP3 inflammasome inhibitor NT-0796, in patients with obesity. NodThera's pioneering approach to obesity treatment is built on the growing understanding of the impact of chronic inflammation on the body and its fundamental role in the complex cycle of weight regulation which balances calorie intake, energy expenditure and satiety. While current drugs have made significant achievements in the management of obesity, their mechanisms primarily suppress the desire to eat (calorie restriction) or they promote a feeling of fullness, ultimately reducing food intake. NodThera's approach goes beyond the reduction of food intake by resetting the body's weight regulatory system and correcting the underlying imbalance, to return the body to its natural metabolic state. Daniel Swisher, Chief Executive Officer of NodThera, commented: 'With its novel molecular mechanism, the convenience of oral dosing without titration, and a well-tolerated safety profile, this fully brain-penetrant NLRP3 inflammasome inhibitor is projected to have a transformative impact on obesity by bringing the body back to balance. I am delighted that, following our recently closed $50 million Series D financing, we have accelerated our lead program into this robust Phase 2 trial, building on an impressive preclinical and clinical data set. This will support the progression of NT-0796 as an enhanced treatment for weight management, to enable patients to achieve sustained and healthy weight loss.' RESOLVE-1 is a randomized, double-blind, placebo-controlled Phase 2 trial that will evaluate the efficacy and safety of NT-0796 in patients with obesity, with or without type 2 diabetes, over 24 weeks. 160 patients are expected to be randomized into three treatment groups, receiving twice daily oral NT-0796, once daily oral NT-0796 or placebo. The trial's primary endpoint is the change in body weight in participants from baseline to week 24. Secondary endpoints include the impact of NT-0796 on body composition, metabolic biomarkers, and HbA1c levels in participants with type 2 diabetes. Headline data from the study are anticipated in Q2 2026. Returning the body to its natural metabolic balance – homeostasis Earlier preclinical and clinical work undertaken by the Company has demonstrated that NLRP3, an intracellular sensor and master switch that modulates inflammation, plays a key role in controlling obesity and obesity-associated inflammation. The fully brain-penetrant NT-0796 reduces inflammation in the brain, as well as throughout the body, to restore multiple dysregulated cardiometabolic pathways. The inhibition of NLRP3 results in the loss of fat mass, while preserving lean muscle mass, and restores the body's natural metabolic balance (homeostasis), enabling sustainable, enhanced and healthy weight loss. Positive clinical data announced by the Company in June 2024, from a Phase 1b/2a cardiovascular risk study in patients with obesity, confirmed NT-0796's profound anti-inflammatory effect and supported its anti-obesity potential. This followed the publication of preclinical data in the Journal of Pharmacology and Experimental Therapeutics, demonstrating the potential of NT-0796 to reverse diet-induced obesity and inflammation in an animal model of the disease, matching weight loss driven by the GLP-1 receptor agonist, semaglutide. Most recently, data published in the journal Obesity showed the enhanced weight loss effect of NT-0796 when combined with semaglutide in a preclinical obesity model. The potential of NT-0796 to improve the efficacy and tolerability of existing GLP-1RA obesity therapies will be further investigated in NodThera's upcoming Phase 2 combination trial, RESOLVE-2, expected to commence in H2 2025. Alan Watt, President and Chief Scientific Officer of NodThera, added: 'Through central NLRP3 inhibition and the correction of multiple dysregulated pathways in the brain and throughout the body, NT-0796 has the potential to deliver robust weight loss and broad cardiometabolic benefits that go beyond those seen with current therapies. NodThera's treatment approach, restoring the body's natural metabolic balance, would be game-changing.' For more information about NodThera please contact: NodTheraTel: +44 (0) 1223 608130Email: info@ ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@ About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at or follow the Company on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796Philadelphia, PA, June 4, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces that the first patients have been dosed in its Phase 2 RESOLVE-1 (RESolution Of infLammation to treat obesity and cardioVascular disEase) clinical trial investigating the potential of its lead candidate, oral NLRP3 inflammasome inhibitor NT-0796, in patients with obesity. NodThera's pioneering approach to obesity treatment is built on the growing understanding of the impact of chronic inflammation on the body and its fundamental role in the complex cycle of weight regulation which balances calorie intake, energy expenditure and satiety. While current drugs have made significant achievements in the management of obesity, their mechanisms primarily suppress the desire to eat (calorie restriction) or they promote a feeling of fullness, ultimately reducing food intake. NodThera's approach goes beyond the reduction of food intake by resetting the body's weight regulatory system and correcting the underlying imbalance, to return the body to its natural metabolic state. Daniel Swisher, Chief Executive Officer of NodThera, commented: 'With its novel molecular mechanism, the convenience of oral dosing without titration, and a well-tolerated safety profile, this fully brain-penetrant NLRP3 inflammasome inhibitor is projected to have a transformative impact on obesity by bringing the body back to balance. I am delighted that, following our recently closed $50 million Series D financing, we have accelerated our lead program into this robust Phase 2 trial, building on an impressive preclinical and clinical data set. This will support the progression of NT-0796 as an enhanced treatment for weight management, to enable patients to achieve sustained and healthy weight loss.' RESOLVE-1 is a randomized, double-blind, placebo-controlled Phase 2 trial that will evaluate the efficacy and safety of NT-0796 in patients with obesity, with or without type 2 diabetes, over 24 weeks. 160 patients are expected to be randomized into three treatment groups, receiving twice daily oral NT-0796, once daily oral NT-0796 or placebo. The trial's primary endpoint is the change in body weight in participants from baseline to week 24. Secondary endpoints include the impact of NT-0796 on body composition, metabolic biomarkers, and HbA1c levels in participants with type 2 diabetes. Headline data from the study are anticipated in Q2 2026. Returning the body to its natural metabolic balance – homeostasis Earlier preclinical and clinical work undertaken by the Company has demonstrated that NLRP3, an intracellular sensor and master switch that modulates inflammation, plays a key role in controlling obesity and obesity-associated inflammation. The fully brain-penetrant NT-0796 reduces inflammation in the brain, as well as throughout the body, to restore multiple dysregulated cardiometabolic pathways. The inhibition of NLRP3 results in the loss of fat mass, while preserving lean muscle mass, and restores the body's natural metabolic balance (homeostasis), enabling sustainable, enhanced and healthy weight loss. Positive clinical data announced by the Company in June 2024, from a Phase 1b/2a cardiovascular risk study in patients with obesity, confirmed NT-0796's profound anti-inflammatory effect and supported its anti-obesity potential. This followed the publication of preclinical data in the Journal of Pharmacology and Experimental Therapeutics, demonstrating the potential of NT-0796 to reverse diet-induced obesity and inflammation in an animal model of the disease, matching weight loss driven by the GLP-1 receptor agonist, semaglutide. Most recently, data published in the journal Obesity showed the enhanced weight loss effect of NT-0796 when combined with semaglutide in a preclinical obesity model. The potential of NT-0796 to improve the efficacy and tolerability of existing GLP-1RA obesity therapies will be further investigated in NodThera's upcoming Phase 2 combination trial, RESOLVE-2, expected to commence in H2 2025. Alan Watt, President and Chief Scientific Officer of NodThera, added: 'Through central NLRP3 inhibition and the correction of multiple dysregulated pathways in the brain and throughout the body, NT-0796 has the potential to deliver robust weight loss and broad cardiometabolic benefits that go beyond those seen with current therapies. NodThera's treatment approach, restoring the body's natural metabolic balance, would be game-changing.' For more information about NodThera please contact: NodTheraTel: +44 (0) 1223 608130Email: info@ ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@ About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at or follow the Company on LinkedIn.
Yahoo
30-04-2025
- Health
- Yahoo
NodThera's Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1
Philadelphia, PA, April 30, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the publication of preclinical data demonstrating the potential of its clinical-stage, oral NLRP3 inflammasome inhibitor NT-0796 to augment existing GLP-1 receptor agonist (GLP-1RA) obesity therapies to deliver enhanced weight loss and sustained weight management. These data, published in the research journal Obesity, show that combined dosing of NodThera's NT-0796 with semaglutide (Wegovy®) drove greater weight loss than either monotherapy in an animal model of obesity. Treatment with the fully brain-penetrating NLRP3 inflammasome inhibitor also sharply limited weight regain following the cessation of semaglutide therapy and reduced multiple cardiovascular, inflammatory and metabolic biomarkers. Despite the significant achievements of GLP-1RAs in the management of obesity, their use is impacted by challenges related to tolerability and the weight regain following discontinuation of treatment. NodThera is pioneering a new approach to obesity treatment built on the growing understanding of the impact of chronic inflammation on the body and its underlying role in the complex cycle of weight regulation. These new data build on NodThera's earlier preclinical and clinical work and support the potential of central NLRP3 inhibition to reset multiple dysregulated cardiometabolic pathways, restoring the body's natural metabolic balance and enabling sustained and healthy weight loss. Enhanced weight loss effects of NT-0796 and semaglutide in combinationIn NodThera's latest publication, the researchers show that weight loss induced by a combination of NT-0796 and semaglutide was nearly two-fold higher at 23% over 28 days compared to semaglutide monotherapy in a high fat diet murine obesity model. Weight loss was further enhanced on the combination therapy when animals were switched for a further 28 days to a polyunsaturated fatty acid diet, intended to be more reflective of a typical human diet. Animals receiving the combination therapy experienced continued weight loss, completely reversing their obese state, with a weight loss of >30% to achieve a weight comparable to animals fed a standard control diet. Hypothalamic (brain) inflammation was also reversed among animals maintained on the combination therapy. Prevention of weight regain post-semaglutide treatment In animals who were switched to NT-0796 monotherapy, following treatment with either semaglutide alone or the NT-0796 and semaglutide combination, the degree of weight regain was highly reduced compared to animals who stopped all therapy. Potential of NLRP3 inhibition to enable a healthy weight lossDEXA scans determined that combination therapy increased fat mass loss whilst preserving lean mass. Calorie intake was also further reduced in animals on the combination therapy, but the degree of fat mass loss observed suggests additional mechanisms, such as enhanced energy expenditure, may contribute. This supports a model consistent with the observed reduction in both peripheral and hypothalamic (brain) inflammation as a druggable mechanism in obesity pathogenesis. Daniel Swisher, Chief Executive Officer of NodThera, commented: 'These data further reinforce our belief in the potential of our brain-targeting NLRP3 inflammasome inhibitor to deliver a step change in the management of obesity. While the efficacy of existing treatments is not in doubt, there are many limitations and challenges to their real-world use by patients. The opportunity to provide patients with a highly effective oral therapy with a well-tolerated safety profile and without titration complexities is compelling and supported by our growing body of evidence indicating NT-0796's potential as monotherapy and in combination to improve the efficacy and tolerability of existing treatments, or even as a follow-on therapy to sustain weight loss.' Alan Watt, President and Chief Scientific Officer of NodThera, added: 'By harnessing both peripheral and central NLRP3 inhibition to correct multiple dysregulated pathways in the brain and throughout the body we have the potential to bring profound cardiometabolic benefits to patients, establishing an enhanced treatment approach to weight management that would enable sustained and healthier weight loss.' NodThera is currently preparing to initiate a robust Phase 2 obesity study of NT-0796, expected in 2Q 2025. Details about the trial's design will be communicated upon initiation of dosing. For more information about NodThera please contact: NodTheraTel: +44 (0) 1223 608130Email: info@ ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@ About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at or follow the Company on in to access your portfolio
Globe and Mail
16-04-2025
- Business
- Globe and Mail
NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsigh
"NLRP3 Protein Inhibitors Clinical Trials" NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others. (Albany, USA) DelveInsight's 'NLRP3 Protein Inhibitors Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NLRP3 protein inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the NLRP3 protein inhibitors pipeline domain. The potential for NLRP3 inhibitors extends beyond autoimmune and inflammatory diseases. Ongoing research suggests they may also be effective in treating neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, as well as metabolic conditions like gout and non-alcoholic steatohepatitis (NASH). This broad range of applications is driving market interest. The NLRP3 protein inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NLRP3 protein inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the NLRP3 protein inhibitors clinical trial landscape. Key Takeaways from the NLRP3 Protein Inhibitors Pipeline Report DelveInsight's NLRP3 protein inhibitors pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline NLRP3 protein inhibitors. Key NLRP3 protein inhibitors companies such as Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others are evaluating new NLRP3 protein inhibitors drugs to improve the treatment landscape. Promising pipeline NLRP3 protein inhibitors such as HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others are under different phases of NLRP3 protein inhibitors clinical trials. In August 2024, Halia Therapeutics and Biolexis Therapeutics announced an ongoing collaboration that successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis' MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in developing treatments for neuroinflammatory disorders, including Parkinson's disease and other neurodegenerative conditions. In June 2024, NodThera announced positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters. In May 2024, Novo Nordisk successfully dosed the first participant in a Phase I clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022. In April 2024, Ventus Therapeutics announced results from its Phase I clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor. The Phase I trial evaluated the pharmacodynamics, pharmacokinetics, safety, and tolerability of VENT-02 across a broad range of single and multiple ascending doses in adult healthy volunteers. In March 2024, Parkinson's UK announced the investment of GBP 2.1 million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson's. NLRP3 Protein Inhibitors Overview NOD-like receptor family pyrin domain-containing 3 (NLRP3) protein is a key component of the innate immune system, playing a crucial role in the activation of the inflammasome. The NLRP3 inflammasome is responsible for the maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18. This process is essential for host defense against pathogens but can lead to chronic inflammation when dysregulated. Overactivation of the NLRP3 inflammasome is implicated in a wide range of diseases, including autoimmune disorders, metabolic syndromes, neurodegenerative diseases, and certain cancers. Thus, targeting NLRP3 with specific inhibitors has become a promising strategy for treating these inflammatory conditions. NLRP3 protein inhibitors work by either directly blocking the NLRP3 protein or interfering with its activation pathway, thereby preventing the assembly of the inflammasome and subsequent cytokine release. These inhibitors offer a novel therapeutic approach by addressing the root cause of inflammation rather than merely managing its symptoms. Several NLRP3 inhibitors are currently under development, with some already in clinical trials for diseases like gout, rheumatoid arthritis, and type 2 diabetes. Their ability to modulate the inflammatory response makes them a potential game-changer in the treatment of chronic inflammatory diseases, offering hope for more effective and targeted therapies. A snapshot of the Pipeline NLRP3 Protein Inhibitors Drugs mentioned in the report: Nibrozetone: EpicentRx ZYIL 1: Zydus Cadila HT6184: Halia Therapeutics VTX 3232: Ventyx Biosciences VENT 02: Ventus Therapeutics NNC6022-0001: Novo Nordisk Kamuvudine-9: Inflammasome Therapeutics MRT-8102: Monte Rosa Therapeutics Learn more about the emerging NLRP3 protein inhibitors @ NLRP3 Protein Inhibitors Medication and FDA approval NLRP3 Protein Inhibitors Therapeutics Assessment The NLRP3 protein inhibitors pipeline report proffers an integral view of the emerging NLRP3 protein inhibitors segmented by stage, product type, molecule type, and route of administration. Scope of the NLRP3 Protein Inhibitors Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule Key NLRP3 Protein Inhibitors Companies: Monte Rosa Therapeutics (NASDAQ: GLUE), Ventyx Biosciences (NASDAQ: VTYX), Zydus Lifesciences Limited (BSE: 532321, NSE: ZYDUSLIFE), and Novo Nordisk (NYSE: NVO, OMX: NOVO-B), Halia Therapeutics, Ventus Therapeutics, EpicentRx, Inflammasome Therapeutics, Biolexis Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, and NodThera, and others Key NLRP3 Protein Inhibitors Pipeline Therapies: HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others Dive deep into rich insights for new NLRP3 protein inhibitors, visit @ NLRP3 Protein Inhibitors Therapies and Drugs Table of Contents 1. NLRP3 Protein Inhibitors Pipeline Report Introduction 2. NLRP3 Protein Inhibitors Pipeline Report Executive Summary 3. NLRP3 Protein Inhibitors Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. NLRP3 Protein Inhibitors Clinical Trial Therapeutics 6. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Pre-registration) 7. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Phase III) 8. NLRP3 Protein Inhibitors Pipeline: Mid-Stage Products (Phase II) 9. NLRP3 Protein Inhibitors Pipeline: Early-Stage Products (Phase I) 10. NLRP3 Protein Inhibitors Pipeline Therapeutics Assessment 11. Inactive Products in the NLRP3 Protein Inhibitors Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the NLRP3 Protein Inhibitors Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
